Table 4.

Clinical relapses in patients from Hospital Teplice.¹

NO. OF PATIENTS WITH AT LEAST 1 CLINICAL RELAPSE (ALL)		p value
In 90 days after vaccination	15 (3.81%)
Between 0–90 days before vaccination	9 (2.28%)	0.307
Between 90–180 days before vaccination	11 (2.79%)	0.540
Between 180–270 days before vaccination	7 (1.78%)	0.135
Between 360–270 days before vaccination	17 (4.31%)	0.850
In 90 days after COVID-19	12 (4.48%)
Between 0–90 days before COVID-19	14 (5.22%)	0.844
Between 90–180 days before COVID-19	15 (5.60%)	0.663
Between 180–270 days before COVID-19	11 (4.10%)	1.000
Between 270–360 days before COVID-19	10 (3.73%)	0.831
NO. OF PATIENTS WITH AT LEAST 1 CLINICAL RELAPSE (PATIENTS WITH DMT CHANGES EXCLUDED)
In 90 days after vaccination	13 (3.38%)	0.264
Between 0 - 90 days before vaccination	7 (1.82%)
In 90 days after vaccination	13 (3.42%)	0.522
Between 90 - 180 days before vaccination	9 (2.36%)
In 90 days after vaccination	13 (3.47%)	0.010
Between 180 - 270 days before vaccination	2 (0.53%)
In 90 days after vaccination	13 (3.51%)	0.502
Between 270 - 360 days before vaccination	9 (2.43%)
In 90 days after COVID-19	11 (4.42%)	1.000
Between 0 - 90 days before COVID-19	11(4.42%)
In 90 days after COVID-19	11 (4.70%)	0.267
Between 90 - 180 days before COVID-19	6 (2.56%)
In 90 days after COVID-19	11 (4.89%)	0.332
Between 180 - 270 days before COVID-19	6 (2.67%)
In 90 days after COVID-19	11 (5.16%)	0.027
Between 270 - 360 days before COVID-19	2 (0.94%)

DMT = disease modifying therapy; 1. 394 MS patients from Hospital Teplice were vaccinated, 268 experienced COVID-19.